RxDoctor Payments Data

Pankaj Srivastava, MD

Internal Medicine · Dyersburg, TNNPI 1487655957

Payments from drug & device makers

$574in general payments, 2019–2025

Across 31 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$85
  • Otsuka America Pharmaceutical, Inc.$71
  • Johnson & Johnson$65
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • Pfizer$58
  • Novartis$33
  • plus $200 from 10 others

What the payments were for

  • Food & beverage$574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$574 in reported general payments places this provider in the 60th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$240,586
Medicare patients
274
Services billed
4,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol97$69,353
EliquisApixaban84$67,401
JanuviaSitagliptin Phosphate65$61,254
OzempicSemaglutide52$56,689
VraylarCariprazine Hcl36$50,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$45,287
RexultiBrexpiprazole32$44,791
EntrestoSacubitril/Valsartan29$29,368
LinzessLinaclotide45$28,865
XareltoRivaroxaban32$24,107
TradjentaLinagliptin20$15,584
Lurasidone Hcl30$11,769
JardianceEmpagliflozin13$10,941
Janumet XrSitagliptin Phos/Metformin Hcl17$10,357
SymbicortBudesonide/Formoterol Fumarate39$9,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess$24$79,46281 claims
AstraZenecaFarxiga, Symbicort$13$79,260136 claims
MerckJanuvia, Janumet Xr$12$71,61182 claims
PfizerEliquis$58$67,40184 claims
Otsuka America Pharmaceutical, Inc.Rexulti$71$44,79132 claims
NovartisEntresto$33$29,36829 claims
Johnson & JohnsonXarelto$65$24,10732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Dyersburg

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →